BR0110211A - Derivados de oxadiazol tendo efeitos anticâncer - Google Patents

Derivados de oxadiazol tendo efeitos anticâncer

Info

Publication number
BR0110211A
BR0110211A BR0110211-7A BR0110211A BR0110211A BR 0110211 A BR0110211 A BR 0110211A BR 0110211 A BR0110211 A BR 0110211A BR 0110211 A BR0110211 A BR 0110211A
Authority
BR
Brazil
Prior art keywords
oxadiazole derivatives
optionally substituted
anticancer effects
prodrug
solvate
Prior art date
Application number
BR0110211-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Takayuki Yoshioka
Ryuji Maekawa
Fumihiko Watanabe
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of BR0110211A publication Critical patent/BR0110211A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BR0110211-7A 2000-04-21 2001-04-16 Derivados de oxadiazol tendo efeitos anticâncer BR0110211A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000120234 2000-04-21
PCT/JP2001/003214 WO2001083463A1 (en) 2000-04-21 2001-04-16 Oxadiazole derivatives having anticancer effects

Publications (1)

Publication Number Publication Date
BR0110211A true BR0110211A (pt) 2003-06-03

Family

ID=18631080

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110211-7A BR0110211A (pt) 2000-04-21 2001-04-16 Derivados de oxadiazol tendo efeitos anticâncer

Country Status (16)

Country Link
US (2) US6720343B2 (2)
EP (1) EP1277744A4 (2)
JP (1) JP3974781B2 (2)
KR (1) KR100542780B1 (2)
CN (1) CN1199956C (2)
AU (2) AU4691601A (2)
BR (1) BR0110211A (2)
CA (1) CA2406685C (2)
HU (1) HUP0300619A3 (2)
MX (1) MXPA02010325A (2)
NO (1) NO324868B1 (2)
PL (1) PL203161B1 (2)
RU (1) RU2275371C2 (2)
TW (1) TWI294877B (2)
WO (1) WO2001083463A1 (2)
ZA (1) ZA200208307B (2)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
EP1650199A4 (en) * 2003-07-30 2008-11-19 Shionogi & Co SULPHONAMIDE DERIVATIVE WITH ISOXAZOL RING
CA2583681A1 (en) * 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
GB0601744D0 (en) * 2006-01-27 2006-03-08 Novartis Ag Organic compounds
EP2258700A1 (en) * 2006-05-09 2010-12-08 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
KR100783585B1 (ko) 2006-08-22 2007-12-07 한국생명공학연구원 스탯의 활성을 저해하는 옥사다이아졸 우레아 화합물을 유효성분으로 함유하는 암의 예방 또는 치료제
KR101669432B1 (ko) 2007-08-27 2016-10-26 다트 뉴로사이언스 (케이만) 엘티디. 치료적 이속사졸 화합물
MX2010005889A (es) * 2007-12-10 2010-06-22 Actelion Pharmaceuticals Ltd Derivados de tiofeno como agonistas de s1p1/edg1.
UY32858A (es) 2009-08-31 2011-03-31 Abbott Healthcare Products Bv Derivados de (tio)morfolina como moduladores de sip
RU2415845C1 (ru) * 2009-10-14 2011-04-10 Государственное образовательное учреждение высшего профессионального образования "Астраханский государственный университет" (АГУ) Сульфонные производные 2-нитро-2-(3-арил-1,2,4-оксадиазол-5-ил)этана, обладающие противолепрозной и противотуберкулезной активностью
TW201206893A (en) 2010-07-09 2012-02-16 Abbott Healthcare Products Bv Bisaryl (thio) morpholine derivatives as S1P modulators
TWI522361B (zh) 2010-07-09 2016-02-21 艾伯維公司 作為s1p調節劑的稠合雜環衍生物
TW201643169A (zh) 2010-07-09 2016-12-16 艾伯維股份有限公司 作為s1p調節劑的螺-哌啶衍生物
CN103450167A (zh) * 2012-05-28 2013-12-18 南京大学 一类含1,3,4-噁二唑和吡嗪环的酰腙类衍生物及其制备方法与用途
US10710994B2 (en) * 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
US11535632B2 (en) 2019-10-31 2022-12-27 ESCAPE Bio, Inc. Solid forms of an S1P-receptor modulator
CN113264899B (zh) * 2021-04-09 2022-06-14 台州学院 一种1，3，5-噁二嗪类化合物及其制备和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3621427B2 (ja) * 1997-07-22 2005-02-16 塩野義製薬株式会社 糸球体障害治療または予防剤
AU5647099A (en) * 1998-09-11 2000-04-03 Shionogi & Co., Ltd. Remedal or preventive agent for congestive heart failure

Also Published As

Publication number Publication date
PL359415A1 (en) 2004-08-23
KR100542780B1 (ko) 2006-01-11
EP1277744A1 (en) 2003-01-22
NO20025035L (no) 2002-12-19
AU2001246916B2 (en) 2004-10-07
KR20030019357A (ko) 2003-03-06
WO2001083463A1 (en) 2001-11-08
US6720343B2 (en) 2004-04-13
CA2406685C (en) 2006-10-31
JP3974781B2 (ja) 2007-09-12
NO20025035D0 (no) 2002-10-18
HUP0300619A3 (en) 2006-02-28
MXPA02010325A (es) 2003-04-25
US20040122066A1 (en) 2004-06-24
PL203161B1 (pl) 2009-08-31
TWI294877B (2) 2008-03-21
US20030203940A1 (en) 2003-10-30
NO324868B1 (no) 2007-12-17
HUP0300619A2 (hu) 2003-07-28
AU4691601A (en) 2001-11-12
CN1199956C (zh) 2005-05-04
EP1277744A4 (en) 2007-07-11
RU2275371C2 (ru) 2006-04-27
ZA200208307B (en) 2003-10-15
CA2406685A1 (en) 2002-10-17
CN1436179A (zh) 2003-08-13

Similar Documents

Publication Publication Date Title
BR0110211A (pt) Derivados de oxadiazol tendo efeitos anticâncer
CY1106166T1 (el) Παραγωγα κουιναζολινης ως αναστολεις vegf.
BG104998A (en) Isothiazole derivatives useful as anticancer agents
DE69528005D1 (de) Prolineamid-Derivate
DK0928788T3 (da) Imidazolidin-4-on-derivater, der er nyttige som anticancer-midler
PA8480201A1 (es) Derivados de quinilin-2-ona utiles como agentes contra el cancer
ATE322264T1 (de) Medizinische zusammensetzungen als begleittherapie gegen krebs
MXPA03002839A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7.
NO20015172L (no) 1-metyl-erytromycin-derivater
FR2676444B1 (fr) Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
PT842923E (pt) Derivados do pirrolo e composicoes medicinais
BR0113389A (pt) Compostos que inibem a atividade do fator xa
BRPI0518231A2 (pt) derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica
AU2003223340A8 (en) Certain pharmaceutically useful substituted aminoalkyl heterocycles
ATE247964T1 (de) Als inhibitoren der aicarftnützliche verbindungen
DE69931378D1 (de) Chinazolin derivate und therapeutische verwendungen davon
TR200200485T2 (tr) Yeni A-500359 türevleri.
PA8450901A1 (es) Derivados de eritromicina
EE200200688A (et) Akrüloüüldistamütsiini derivaati, mikrotuubulivastast toimeainet ja/või antimetaboliiti sisaldav farmatseutiline kompositsioon, derivaadi kasutamine tuumorivastase ravimi valmistamiseks ning kombineeritud ravimpreparaat
AP2002002669A0 (en) Hygromycin a derivatives for the treatment of bacterial and protozoal infections.
WO2002022567A8 (en) Novel thio derivatives of sordarin as antifungal agents
ECSP982501A (es) Derivados de eritromicina

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2156 DE 02/05/2012.